



HARMONY

Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology

Press Release

HARMONY Alliance: Challenges and Opportunities for Using Big Data to Treat Hematological Malignancies (HMs)

20 October 2017, Berlin, Germany

On October 23rd and 24th, representatives from the 51 HARMONY Alliance Partners and Associated Members will meet in Berlin to improve the treatment of HMs through the use of Big Data technologies.

How can HARMONY help patients suffering from hematologic malignancies (HMs) to gain access to the right treatment at the right time? The HARMONY Alliance was designed as a resourceful medicine offensive to battle neoplasms in hematology. Innovation is key in the design of breakthrough drugs, in easing the route for medicines to get from bench to bedside, and ultimately in finding the right treatment at the right time for HM patients.

During the General Assembly, partners and members will discuss challenges, lessons learned, and opportunities for research in HMs, especially in relation to multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-hodgkin's lymphoma (NHL), myelodysplastic syndromes (MDS), and pediatric hematologic malignancies (HMs).

The keynote speaker is Alan List from the Moffit Cancer Center, who will elaborate on the initiatives taking place in Big Data and hemato-oncology in the United States. The two-day program will provide ample opportunity for networking and targeted meetings on specific issues, varying from data governance and analysis modelling to ethical considerations in relation to Big Data. The yield of ongoing work packages will be discussed and the roadmap for the second year of this five-year project will be defined.

HARMONY is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to enhance the development of better and safer medicines for patients. HARMONY is IMI's ace alliance in the HM area.

Interested in starting a research project with big data analyses from HARMONY? Please contact the HARMONY Coordination Office at the Institute of Biomedical Research of Salamanca (IBSAL) at harmonyoffice@ibsal.es.

HARMONY: Providing the right treatment at the right time for HM patients.

Contact

- HARMONY Communications
European Hematology Association (EHA), The Hague, The Netherlands
Ellen de Waal, +31 70 3020099 or +31 654 711703, communications@harmony-alliance.eu

About HARMONY

- HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Disclaimer

- It should be made clear in the text and layout that the communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.